{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:47:05Z","timestamp":1776919625263,"version":"3.51.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are significant interindividual variations in voriconazole (VCZ) blood concentrations, which affect both treatment efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our goal is to identify the factors influencing VCZ trough concentrations and provide new evidence for individualized dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 281 hospitalized patients receiving VCZ were enrolled. Demographic, liver and kidney function, C-reactive protein (CRP) and other clinical data were collected. Trough concentrations were determined using HPLC. Multivariate linear regression and ordinal logistic regression were employed to identify influencing factors, with predictive performance assessed by ROC curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CRP is a significant positive predictor of VCZ trough concentration (B = 0.010,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.006), demonstrating the strongest predictive capability for elevated trough levels (&amp;gt;5 \u03bcg\/mL) (AUC = 0.8864,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001), outperforming conventional liver function indicators such as total bile acids (AUC = 0.6326). Loading dose also showed a significant correlation with increased trough concentration (B = 0.973,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.007) and elevated the risk of supratherapeutic levels (OR = 0.430,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.006). Additionally, weight, albumin, platelet count, and concomitant administration of pantoprazole or dexamethasone were identified as independent influencing factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The high variability in VCZ trough concentrations may be partially attributed to factors such as weight, loading dose, liver function, inflammation and concomitant medications. Although loading doses enable rapid efficacy, they increase the risk of supratherapeutic concentrations. Patients in the high-CRP group are more likely to exceed 5.0 \u03bcg\/mL, demonstrating the best discriminative ability for predicting excessively high concentrations. These findings provide new evidence for VCZ dose optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1745737","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:22:08Z","timestamp":1776918128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors affecting trough concentrations of voriconazole: a dual-center retrospective analysis focusing on loading dose and inflammatory state effects"],"prefix":"10.3389","volume":"17","author":[{"given":"Feng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Hunan University of Medicine General Hospital","place":["Huaihua, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Department of Oncology, Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Yunnan Province","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Hospital of Changsha","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Department of Pharmacy, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hunan University of Medicine General Hospital","place":["Huaihua, China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Department of Pharmacy, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"College of Pharmacy, Changsha Medical University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40780-016-0044-9","article-title":"A retrospective analysis of patient-specific factors on voriconazole clearance","volume":"2","author":"Dote","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1128\/aac.04789-14","article-title":"Influence of inflammation on voriconazole metabolism","volume":"59","author":"Encalada Ventura","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1111\/bcp.14661","article-title":"Optimization of voriconazole therapy for treatment of invasive aspergillosis: pharmacogenomics and inflammatory status need to be evaluated","volume":"87","author":"Gautier-Veyret","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bcp.15916","article-title":"Individualized treatment with voriconazole in the Chinese population: inflammation level as a novel marker for dose optimization","volume":"90","author":"Hao","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s13318-024-00915-2","article-title":"Pharmacokinetic model of drug interaction of tacrolimus with combined administration of CYP3A4 inhibitors voriconazole and clarithromycin after bone marrow transplantation","volume":"49","author":"Hirai","year":"2024","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00228-023-03538-9","article-title":"Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients","volume":"79","author":"Hu","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1575233","DOI":"10.3389\/fphar.2025.1575233","article-title":"Therapeutic drug monitoring of voriconazole and the impact of inflammation on plasma trough concentrations in children","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00228-022-03359-2","article-title":"External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy","volume":"78","author":"Huang","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e13887","DOI":"10.1111\/cts.13887","article-title":"Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole","volume":"17","author":"Klomp","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of therapeutic drug monitoring and cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review","volume":"55","author":"Lee","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/1120009x.2023.2247208","article-title":"Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population","volume":"36","author":"Li","year":"2024","journal-title":"J. Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1455721","DOI":"10.3389\/fphar.2024.1455721","article-title":"Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis","volume":"15","author":"Ling","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1248\/bpb.b22-00097","article-title":"Impact of inflammation on intra-individual variation in trough voriconazole concentration in patients with hematological malignancies","volume":"45","author":"Maeda","year":"2022","journal-title":"Biol. Pharm. Bull."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/aac.00884-15","article-title":"In vitro study of the variable effects of proton pump inhibitors on voriconazole","volume":"59","author":"Niece","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","article-title":"Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole","volume":"49","author":"Qi","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","article-title":"Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism","volume":"51","author":"Schulz","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/bcp.13627","article-title":"Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole","volume":"84","author":"Vreugdenhil","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on monte carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00228-020-02831-1","article-title":"Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms","volume":"76","author":"Zeng","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3390\/antibiotics10121542","article-title":"Factors affecting voriconazole trough concentration and optimal maintenance voriconazole dose in Chinese children","volume":"10","author":"Zhao","year":"2021","journal-title":"Antibiot. (Basel)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1745737\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:22:09Z","timestamp":1776918129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1745737\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":23,"alternative-id":["10.3389\/fphar.2026.1745737"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1745737","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1745737"}}